Analyst Geoff Meacham's $18 price objective implies a potential upside of 51% from the stock's $11.94 closing price Monday. Meacham cited the firm's strong pipeline of novel drugs and treatments as a catalyst. Specifically, Neumora's navacaprant drug could be a "game-changer for major depressive disorder," Meacham said. "Overall, the diverse pipeline and targets provide multiple opportunities for Neumora to potentially become one of the largest neuro-focused biotech companies." While the company is currently unprofitable, Meacham expects this to change in 2027, or one year after the company officially commercializes navacaprant for major depressive disorders.

---

Persons: Geoff Meacham's, Meacham, — CNBC's Michael Bloom Organizations: Bank of America